An association between positive (score 2+ or 3+) ERBB2 expression according to the ASCO/CAP guidelines in BC and high grade (p = 0.012), and between ERBB2 positivity and the presence of an ERBB2 amplification or gain (p < 0.001), but not for growth pattern, necrosis, stage, and other clinicopathological parameters (p > 0.05) was noted (Table 3). Here, ERBB2 is linked to breast cancer.